Cerebral adrenoleukodystrophy (CALD) is a rare progressive, genetic brain disease that primarily presents in young boys, causing loss of neurological function and ultimately leading to early death.

More than anything in the world, 3-year-old Kiri Duke-Rosati has been hoping this month that Santa Claus would bring him ...

Dublin, July 11, 2025 (GLOBE NEWSWIRE) -- The "Adrenoleukodystrophy Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to bluebird bio Inc for elivaldogene autotemcel, its gene therapy that aims ...

A gene therapy to treat cerebral adrenoleukodystrophy (CALD) -- a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis -- effectively stabilized the disease's ...

We conducted a randomized, double-blind, placebo-controlled, crossover trial comparing lovastatin at a dose of 40 mg once daily with placebo (Current Controlled Trials number, ISRCTN31565393). Outcome ...

In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) -- a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis -- ...

X-linked adrenoleukodystrophy (X-ALD) is a debilitating disease caused by mutations in the ABCD1 gene. Approximately 30% of affected boys develop the progressive ...

(MENAFN- GlobeNewsWire - Nasdaq) The global adrenoleukodystrophy market is in a growth stage, driven by advancements in gene and drug therapies, improved diagnostic capabilities like newborn screening ...

The evidence presented above document a role for VLCFAs in peroxisomal dysfunction that lead to elevated ROS, oxidative stress and the subsequent inflammatory demyelination observed in ALD patients.